Fennec Pharmaceuticals (FENC) Total Debt (2021 - 2022)

Fennec Pharmaceuticals' (FENC) quarterly Total Debt came in at $25.0 million in Q4 2022, up 265.87% YoY from $6.8 million in Q4 2021, and little changed on a QoQ basis from $25.0 million in Q3 2022.

Fennec Pharmaceuticals (FENC) Total Debt (2021 - 2022) Analysis & Trends

Fennec Pharmaceuticals (FENC) has 2 years of Total Debt data on file, last reported at $25.0 million in Q4 2022.

  • Quarterly Total Debt rose 265.87% year-over-year to $25.0 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $25.0 million (up 265.87% YoY) and the FY2022 annual result came in at $25.0 million, up 265.87% from the prior year.
  • Total Debt was little changed at $25.0 million in Q4 2022, from $25.0 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $25.0 million in Q3 2022 to a low of $1.8 million in Q3 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1.07 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 9.34 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 546.77 Mn
10 Fennec Pharmaceuticals 410.60 Mn 369.35 Mn 17.15 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2022 25.00 Mn
Sep 30, 2022 25.00 Mn
Jun 30, 2022 5.00 Mn
Mar 31, 2022 5.00 Mn
Dec 31, 2021 6.83 Mn
Sep 30, 2021 1.83 Mn
Jun 30, 2021 2.00 Mn